Table 1.
Potency of ASV and VX-950 against recombinant full-length HCV NS3/4A protease complexes representing different HCV genotypes
| Genotype (strain) | IC50 (nM)a |
|
|---|---|---|
| ASV | VX-950b | |
| 1a (H77) | 0.70 ± 0.06 | 12 ± 2 |
| 1b (J4L6S) | 0.30 ± 0.02 | 22 ± 6 |
| 2a (HC-J6) | 15 ± 1 | 95 ± 17 |
| 2b (HC-J8) | 78 ± 2 | 12 ± 1 |
| 3a (S52) | 320 ± 13 | 537 ± 4 |
| 4a (ED43) | 1.6 ± 0.1 | 12 ± 1 |
| 5a (SA13) | 1.7 ± 0.2 | 38 ± 3 |
| 6a (HK-6A) | 0.9 ± 0.1 | 86 ± 2 |
a
Data are means ± standard deviations from at least three independent experiments.
b
VX-950 was preincubated with each of the respective NS3/4A protease complexes for 30 min before the addition of substrate to obtain optimum potency. Preincubation of ASV and enzyme was not required to enhance potency.